While AI’s ability to weaponize biology is not widely discussed, seed-stage investors are betting heavily on biosecurity startups leveraging AI. Recently, two companies have raised significant seed funding with OpenAI as a notable backer. Valthos, which uses AI to detect biological threats and develop countermeasures, secured $30 million last fall with support from Founders Fund, Lux Capital, and OpenAI. Shortly after, Red Queen Bio raised $15 million, led by OpenAI, focusing on accelerating biosecurity defenses as AI advances. In the nonprofit realm, SecureBio obtained $1.4 million in grants to address pandemic threats.
Though these investments are small compared to the vast AI funding ecosystem—OpenAI alone raised a record $110 billion recently—they mark an emerging wave of startups targeting severe biosecurity challenges, beyond traditional focuses like livestock. Companies like Valthos highlight the alarming reality that biology can now be weaponized faster than cures can be developed. The Red Queen Bio team references the Red Queen hypothesis, emphasizing the need for constant innovation just to maintain safety in this rapidly evolving threat landscape.
This emerging sector reflects a critical and urgent race against evolving biological risks, where lagging behind could have catastrophic consequences.
